Evidence map›Paper›PMID 32035478›Full record

ArticleBMC neurology2020

Rising prevalence of multiple sclerosis in Saudi Arabia, a descriptive study.

Mohammed AlJumah, R Bunyan, H Al Otaibi, G Al Towaijri, A Karim, Y Al Malik, M Kalakatawi, S Alrajeh, M Al Mejally, H Algahtani and 15 more

Registry-linked trialAbstract readMulticenter Study
In one paragraph

Article in BMC neurology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05615454 (Effect of Bio-electromagnetic Energy Regulation Therapy on Erectile Dysfunction in Patients With Multiple Sclerosis), which is not on this map. Cited by 75 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
75citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05615454 naunknown statusnot on this mapstarted 2023, after this paper: background citation

Effect of Bio-electromagnetic Energy Regulation Therapy on Erectile Dysfunction in Patients With Multiple Sclerosis

TypeinterventionalSponsorImam Abdulrahman Bin Faisal UniversityRan2023 to 2024Enrolled50ConditionsErectile Dysfunction Due to Diseases Classified Elsewhere, Multiple Sclerosis, Relapsing-RemittingArmsbio-electromagnetic energy regulation therapy (BEMER) machine model type: B.BOX CLASSIC, model NO: 420100, 12-15 Volt, (BEMER Int.AG, Liechtenstein product)., placebo BEMER
3 · Its place in the literature

Who cites it

75 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Association between lesion location and symptoms of restless leg syndrome (RLS) among patients with multiple sclerosis (MS).Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2026
    Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article

15 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors.

Mohammed AlJumahKing Fahd Medical City (KFMC), MOH, Riyadh, Saudi Arabia. jumahm@gmail.com.
R BunyanKing Fahd Specialist Hospital (KFSH)-Dammam, Dammam, Saudi Arabia.
H Al OtaibiKing Fahd General Hospital-Jeddah, Jeddah, Saudi Arabia.
G Al TowaijriKing Fahd Medical City (KFMC), MOH, Riyadh, Saudi Arabia.
A KarimKing Fahd General Hospital-Al-Madinah, Riyadh, Saudi Arabia.
Y Al MalikKing Abdulaziz Medical City (National Guard Health Affairs)-Riyadh, Riyadh, Saudi Arabia.
M KalakatawiNour Specialized Hospital, Makkah, Saudi Arabia.
S AlrajehDr. Sulaiman Al Habib Hospital-Olaya Branch, Riyadh, Saudi Arabia.
M Al MejallyHeraa General Hospital, Makkah, Saudi Arabia.
H AlgahtaniKing Abdul-Aziz Medical City (National Guard Health Affairs), Jeddah, Saudi Arabia.
A AlmubarakQatif Central Hospital, Qatif, Saudi Arabia.
E CuplerKing Faisal Specialist Hospital & Research Center, Jeddah, Saudi Arabia.
S AlawiPrince Sultan Military Medical City, Riyadh, Saudi Arabia.
S QureshiJohns Hopkins Aramco Healthcare Company (JHAH), Dhahran, Saudi Arabia.
S NahrirKing Saud Medical City, Riyadh, Saudi Arabia.
A AlmalkiKing Abdul-Aziz Hospital and Oncology Center, Jeddah, Saudi Arabia.
A AlhazzaniKing Saud University, Riyadh, Saudi Arabia.
I AlthubaitiKing Fahad Military Medical Complex, Dhahran, Saudi Arabia.
N AlzahraniKing Fahd General Hospital, Baha, Saudi Arabia.
E MohamednourKing Fahad Specialist Hospital, Dammam, Qassim, Saudi Arabia.
J SaeediKing Abdullah Bin Abdulaziz University Hospital, Riyadh, Saudi Arabia.
S IshakItkan Health Consulting, Riyadh, Saudi Arabia.
H AlmudaiheemMinistry of Health, Deputyship of Therapeutic Affairs, Riyadh, Saudi Arabia.
A El-MetwallyKing Saud bin Abdulaziz University For Health Sciences, Riyadh, Saudi Arabia.
A Al-JedaiMinistry of Health, Deputyship of Therapeutic Affairs, Riyadh, Saudi Arabia.

Funding

King Abdulaziz City for Science and Technology (KACST) grant # AT-34-438
6 · The paper itself

Abstract

backgroundIn 2015, the first nationwide, multicenter Multiple Sclerosis (MS) registry was initiated in the Kingdom of Saudi Arabia (KSA) mainly with an objective to describe current epidemiology, disease patterns, and clinical characteristics of MS in Saudi Arabia. This article aimed to report initial findings of the registry and regional prevalence of MS.

methodIn 2015, a national MS registry was launched in KSA to register all MS patient with confirmed diagnosis according to the 2010 McDonald Criteria. The registry aimed to identify and recruit all healthcare facilities treating MS patients in the Kingdom, and collect data such as demographics, clinical characteristics (disease onset, diagnosis, presentation of symptoms at onset, disease course, relapse rate, and disability measures), family history, and treatments. All the included sites have obtained IRB/EC approvals for participating in the registry. Currently, the registry includes 20 hospitals from different regions across the Kingdom. The Projected prevalence was calculated based on the assumption that the number of diagnosed MS cases in participating hospitals (in each region) is similar to the number of cases in remaining nonparticipant hospitals in the same region.

resultsAs of September 2018, the registry has included 20 hospitals from the different regions across the Kingdom and has collected comprehensive data on 2516 patients from those hospitals, with median age 32 (Range: 11-63) and 66.5% being females. The reported prevalence of MS for those hospitals was estimated to be 7.70/100,000 population and 11.80/100,000 Saudi nationals. Based on the assumption made earlier, we projected the prevalence for each region and for the country as a whole. The overall prevalence of MS at the country level was reported to be 40.40/100,000 total population and 61.95/100,000 Saudi nationals. Around 3 out of every 4 patients (77.5%) were 40 years of age or younger. Female to male ratio was 2:1. The prevalence was higher among females, young and educated individuals across all five regions of Saudi Arabia.

conclusionThe prevalence of MS has significantly increased in Saudi Arabia but is still much lower than that in the western and other neighboring countries like Kuwait, Qatar, and the UAE. However, compared to the past rates, Saudi Arabia's projected prevalence of MS through this national study is 40.40/100,000 population, putting the Kingdom above the low risk zone as per Kurtzke classification. The projected prevalence was estimated to be much higher among Saudi nationals (61.95/100,000 Saudi-nationals). The prevalence was higher among female, younger and educated individuals. Further studies are needed to assess the risk factors associated with increased prevalence in Saudi Arabia.

Indexed as

Persons with DisabilitiesAdolescentAdultChildFemaleHumansMaleMiddle AgedMultiple SclerosisPrevalenceRegistriesRisk FactorsSaudi ArabiaYoung AdultMultiple sclerosisPrevalenceRegistrySaudi Arabia

Identifiers

PMID32035478
PMCPMC7007659

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.